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Abstract
Background: Despite recent advances in diagnosis and treatment, cervical cancer continues to be a significant
health problem worldwide. Whereas robot-assisted surgery has advantages over the abdominal approach, and
minimally invasive techniques are being used increasingly, these may be associated with a higher recurrence rate
and lower overall survival than the abdominal approach. The objective of this study was to compare the surgical
and survival outcomes between abdominal radical hysterectomy (ARH) and robotic radical hysterectomy (RRH).
Methods: A retrospective cohort of patients undergoing radical hysterectomy for cervical cancer from 2006 to 2018
was identified. Patients with stage IA to IB cervical cancer were included and grouped: ARH vs. RRH. The RRH group
was further divided into two groups based on the year of enrollment: RRH1 (2006–2012) and RRH2 (2013–2018).
Tumor characteristics, recurrence rate, progression-free survival (PFS), and overall survival (OS) were compared
between the groups. P-values < 0.05 (two-sided) were considered statistically significant.
Results: A total of 310 patients were identified: 142 and 168 underwent ARH and RRH, respectively. RRH1 and RRH2
had 77 and 91 patients, respectively. Interestingly, RRH2 was more likely to have a larger tumor size (1.7 ± 1.4 vs.
2.0 ± 1.1 vs. 2.4 ± 1.7 cm, P = 0.014) and higher stage (P < 0.001) than RRH1. However, RRH2 showed significantly
favorable PFS in contrast to RRH1. There was no difference between ARH and RRH2 in PFS (P = 0.629), whereas
overall, the RRH group showed significantly shorter PFS than the ARH group. In the multivariate analysis, the
institutional learning curve represented by the operation year was one of the significant predictors for PFS (hazard
ratio [HR] 0.065, P = 0.0162), along with tumor size (HR 5.651, P = 0.0241).
Conclusions: The institutional learning curve, represented by the operation year, is one of the most significant
factors associated with outcomes of RRH for early-stage cervical cancer.
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Background
Although the recent widespread implementation of screen-
ing and prevention has decreased the incidence and mortal-
ity rates of cervical cancer, it continues to be a major public
health problem [1]. Patients with early-stage cervical cancer
are universally regarded as being ideal candidates for radical
hysterectomy and pelvic lymph node (LN) dissection [2].
Conventionally, only the abdominal approach has been
performed, but as technology related to minimally inva-
sive surgery (MIS) continues to develop, the mainstream
approach has been shifting to laparoscopic and robot-
assisted surgery in radical hysterectomy [3, 4]. Further,
previous studies have shown that the robot-assisted ap-
proach has several advantages over the abdominal ap-
proach, including decreased blood loss, higher counts of
harvested LNs, fewer major complications, and shorter
hospital stay [5–12].
However, recently released data from the Laparoscopic
Approach to Cervical Cancer (LACC) trial
(NCT00614211) indicated a higher recurrence rate and
lower overall survival (OS) in patients with cervical cancer
who were surgically treated with MIS than in those treated
via the abdominal approach [13]. However, the unfavorable
outcome of the MIS arm in the LACC trial could be a re-
sult of the surgical technique or negligence of the surgeon,
rather than due to the MIS itself.
The aim of our study was to compare patient features,
tumor characteristics, and survival outcomes in a retro-
spective cohort of patients who underwent abdominal
radical hysterectomy (ARH) versus robotic radical hys-
terectomy (RRH) for cervical cancer at a tertiary referral
institution and to evaluate factors that could impact the
oncologic outcomes of RRH.
Methods
Patients
A retrospective cohort of patients who underwent RRH or
ARH for cervical cancer between 2006 and 2018 at Yonsei
Cancer Center, Severance Hospital was identified. Clinical
data, including patient demographics, tumor characteristics,
and clinical outcomes, were abstracted from the electronic
medical records. All patients with a preoperative diagnosis
of cervical cancer of squamous cell, adenocarcinoma, or
adenosquamous histologies with a Federation of
Gynecology and Obstetrics (FIGO) stage (prior to the revi-
sion in 2018) of less than II were included [14]. Those who
received neoadjuvant chemotherapy prior to the surgery,
whose FIGO stage was II, or who had histologies other than
squamous cell, adenocarcinoma, or adenosquamous were
excluded. Progression-free survival (PFS) was defined as the
time interval between surgery and the first evidence of any
recurrence or last follow-up. OS was described as the dur-
ation of time from the date of diagnosis to the date of death
or last follow-up. The study was approved by the Institu-
tional Review Board at Yonsei University College of
Medicine.
Surgical techniques
The type of surgical approach was determined after a
discussion with each patient about the risks and benefits
of both options. All patients in this cohort underwent
type B-to-C radical hysterectomy, as described by Quer-
leu and Morrow [15]. A systematic pelvic lymphadenec-
tomy was performed, which included removal of the
internal iliac nodes, external iliac nodes, obturator
nodes, and common iliac nodes. Since the introduction
of sentinel LN (SLN) biopsy in surgery for cervical
Fig. 1 Flowchart of patient selection. Selection of patients who underwent RRH (a) and ARH (b). RRH, robotic radical hysterectomy; ARH,
abdominal radical hysterectomy; NAC, neoadjuvant chemotherapy
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cancer, it has been performed in our institution at the
discretion of the surgeon [16]. All the radical hysterecto-
mies were performed by the same board-certified gyne-
cologic oncologists at a single tertiary referral hospital
and assisted by gynecologic oncology fellows.
Statistical analysis
Differences in patient demographics and tumor charac-
teristics were compared using the Student’s t test and
Chi-square test where appropriate. Cox proportional
hazards regression analysis was used to estimate hazard
ratios (HRs) and 95% confidence intervals (CIs). The
Kaplan-Meier analysis was used to estimate the change
in survival. P-values < 0.05 (two-sided) were considered
statistically significant. Numerical data are presented as
number (%) or the median ± standard deviation. Statis-
tical analyses were performed using SPSS version 25.0
for Windows (IBM, Chicago, IL, USA) and R Statistical
Software version 3.6.1 (Foundation for Statistical Com-
puting, Vienna, Austria).
Results
Figure 1 shows a flowchart of the patient selection
process. In total, 310 patients were identified, of
whom 142 underwent ARH and 168 underwent RRH.
Patients who underwent RRH between 2006 and 2012
were classified as RRH1, and patients who underwent
RRH between 2013 and 2018 were classified as RRH2.
RRH1 and RRH2 consisted of 77 and 91 patients,
respectively.
Patients in RRH2 were more likely to have a higher
stage, compared with ARH or RRH1 (P < 0.001). The
ARH group was significantly younger than the two other
groups (P = 0.002). Body mass index and cell type were
not significantly different among the three groups
(Table 1). Table 2 presents the outcomes of surgery and
postoperative adjuvant treatments. The ARH group
showed deeper invasiveness (P < 0.001) and more lym-
phovascular space invasion (LVSI; P < 0.001). In RRH2, a
significantly reduced number of harvested LNs was ob-
served, which is expected to be the result of the SLN bi-
opsy introduced in our hospital in 2012. Additionally,
Table 1 Patient characteristics
ARH (N = 142) RRH1 (‘06–'12) (N = 77) RRH2 (‘13–'18) (N = 91) P
Age 49.7 ± 11.3 46.7 ± 10.3 45.3 ± 9.8 0.002
BMI 23.5 ± 3.4 22.8 ± 4.0 23.4 ± 3.2 0.761
Stage < 0.001
1A1 14 (9.9%) 12 (15.6%) 12 (13.2%)
1A2 10 (7.0%) 2 (2.6%) 1 (1.1%)
1B1 90 (63.4%) 63 (81.8%) 68 (74.7%)
1B2 28 (19.7%) 0 10 (11.0%)
Cell type 0.157
SCC 106 (74.6%) 58 (75.3%) 60 (65.9%)
AC 32 (22.5%) 18 (23.4%) 31 (34.1%)
AS 4 (2.8%) 1 (1.3%) 0
ARH Abdominal radical hysterectomy, RRH Robotic radical hysterectomy, BMI Body mass index, SCC Squamous cell carcinoma, AC Adenocarcinoma,
AS Adenosquamous
Table 2 Pathological results and postoperative treatment
ARH (N = 155) RRH1 ('06–'12) (N = 77) RRH2 ('13–'18) (N = 91) P
Depth of invasion 0.8 ± 0.5 0.6 ± 0.6 0.5 ± 0.5 < 0.001
LVSI 55 (50.5%) 21 (27.3%) 19 (20.9%) < 0.001
Harvested pelvic LNs 19.7 ± 9.8 16.6 ± 9.2 9.6 ± 9.0 < 0.001
LN metastasis 16 (11.3%) 4 (5.2%) 9 (9.9%) 0.188
Tumor size 1.7 ± 1.4 2.0 ± 1.1 2.4 ± 1.7 0.014
Postoperative treatment 0.001
RT 28 (19.7%) 5 (6.5%) 4 (4.4%)
POAC 9 (6.3%) 6 (7.8%) 1 (1.1%)
CCRT 9 (6.3%) 7 (9.1%) 11 (12.1%)
ARH Abdominal radical hysterectomy, RRH Robotic radical hysterectomy, LVSI Lymphovascular space invasion, LN Lymph node, RT Radiotherapy, POAC
Postoperative adjuvant chemotherapy, CCRT Concurrent chemoradiotherapy
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RRH2 was more likely to have a larger tumor size than
the ARH group (2.4 ± 1.7 vs. 1.7 ± 1.4 cm, P = 0.014).
In the multivariate analysis, the institutional learning
curve, represented by the year of operation, was one of
the significant predictors for PFS (HR 0.065, P = 0.0162),
along with tumor size (HR 5.651, P = 0.0241) (Table 3).
Moreover, LVSI and postoperative treatments were also
observed to be possible predictors of PFS but did not
reach statistical significance.
PFS was significantly different between the ARH group
and the overall RRH group (P = 0.002), but there was no
difference between the ARH group and RRH2 (P = 0.629;
Fig. 2a, b). OS did not differ significantly between ARH
and RRH, and there was no significant difference among
ARH, RRH1, and RRH2 (Fig. 2c, d).
Discussion
In this study, we compared the surgical outcomes of
ARH and RRH for cervical cancer. In particular, RRH
was analyzed by dividing the cohort according to the
year of surgery into the first half (RRH1) and the latter
half (RRH2). Interestingly, classification according to the
year of performance, which is thought to reflect the in-
stitutional learning curve, was found to be a significant
PFS predictor along with known factors such as tumor
size.
Previous retrospective studies have indicated that there
is no survival difference between robot-assisted and ab-
dominal approaches, which is consistent with our results
[17–21]. In addition, even when stratified by tumor size,
oncologic outcomes were not significantly different be-
tween laparoscopic and abdominal approaches, which
may emphasize the importance of the learning curve
over the mode of surgery itself [22, 23]. In this study, by
changing the viewpoint, a comparative analysis was per-
formed using the year of surgery to reflect the learning
curve of the institution as an independent factor, which
was shown to be the most significant predicting factor
for oncologic prognosis.
The results of the LACC trial, a multi-center random-
ized phase III trial evaluating the long-term survival of
women who underwent minimally invasive radical hys-
terectomy vs. ARH, were presented at the 2018 Society
of Gynecologic Oncology (SGO) annual meeting [13].
This study included patients with stages IA1 with LVSI,
IA2, and IB1 disease and randomized 631 patients to
radical hysterectomy using MIS or abdominal ap-
proaches. The LACC trial was indecisive with respect to
its primary objective of disease-free survival as the CI
crossed the predetermined noninferiority margin of − 7.2
percentage points for MIS (difference, − 10.6 percentage
points; 95% CI − 16.4 to − 4.7, P = 0.87 for noninferior-
ity). However, the secondary endpoints of disease-free
survival and OS favored the open surgery group. The
MIS RH surgery group showed a significantly lower 3-
year disease-free survival and OS rate than the open RH
surgery group (3-year rate, 91.2% vs. 97.1%; HR for dis-
ease recurrence or death from cervical cancer, 3.74; 95%
CI, 1.63 to 8.58). These unexpected results have already
led to a change in practice patterns at many institutions,






HR (95% CI) P
Age, years (continuous) 168 1.025 (0.956–1.099) 0.4894
LC
2006~2012 77 1 (Reference)
2013~2018 91 0.065 (0.007–0.603) 0.0162*
BMI
< 25 130 1 (Reference)
≥ 25 38 0.243 (0.025–2.404) 0.2264
Stage
IB1, IB2 141 1 (Reference)
IA1, IA2 27 0.638 (0.092–4.446) 0.6502
Histology
SCC 118 1 (Reference)
AC & AS 50 1.367 (0.375–4.986) 0.6357
Invasiveness
< 0.3 cm 97 1 (Reference)
≥ 0.3 cm 71 1.139 (0.297–4.363) 0.8493
LVSI
No 128 1 (Reference)
Yes 40 4.590 (0.973–21.659) 0.0543
No. of harvested LNs
< 20 129 1 (Reference)
≥ 20 39 0.325 (0.068–1.557) 0.1597
Metastatic LNs
No 155 1 (Reference)
Yes 13 2.609 (0.424–16.041) 0.3006
Tumor size
< 2 cm 125 1 (Reference)
≥ 2 cm 43 5.651 (1.255–25.448) 0.0241*
Postoperative treatment
Yes 34 1 (Reference) 0.0755
No 134 0.185 (0.029–1.189)
PFS Progression-free survival, HR Hazard ratio, CI Confidential interval, LC
Learning curve, BMI Body mass index, SCC Squamous cell carcinoma, AC
Adenocarcinoma, AS Adenosquamous, LVSI Lymphovascular space invasion, LN
Lymph node; *, P < 0.05
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which now have completely terminated or significantly
reduced the application of MIS for cervical cancer based
on the results of this trial.
In addition, the results of the LACC trial were consist-
ent with those of a retrospective analysis using the Sur-
veillance, Epidemiology, and End Results data of the
National Cancer Institute in the USA, which argues that
the introduction of MIS was associated with an in-
creased mortality rate due to cervical cancer [24]. In the
analysis, MIS was associated with an increased probabil-
ity of mortality within 4 years compared to laparotomy
(9.1% vs. 5.3%). Nonetheless, for patients who had tu-
mors < 2 cm, the HR for death was statistically similar
between the two surgical approaches in the subgroup
analysis. Other retrospective studies concluded that MIS
was associated with decreased survival in women who
had tumors ≥2 cm [25, 26].
Certain points in the LACC trial, however, have faced
criticism. The LACC trial design included surgeons who
could submit data from only 10 MIS cases and 2 un-
edited videos, to exclude the contributing centers’ learn-
ing curve. However, many gynecologic oncologists
suspect that this could not sufficiently support evidence
that properly trained surgeons contributed in the MIS
arm [27]. Also, we should focus on the result that only 7
recurrences (2.2%) were observed in the 312 women in
the open surgery arm, which is an extremely low rate of
recurrence comparing with previous reports, whereas 27
(8.4%) recurrences were noted in the MIS arm, which is
comparative to the data reported in previous studies [18,
19, 23, 28, 29]. This observation suggested that the sur-
geons who already had overcome the learning curve for
MIS; therefore, adopting the MIS approach for cervical
cancer as the first option might have been excluded in
the LACC trial at the beginning. Moreover, despite in-
cluding a combination of both conventional laparoscopy
and robotic surgery in the MIS arm, the enrolment was
heavily skewed toward laparoscopy, and only 15.6% (N =
45) of women had undergone robotic hysterectomy.
Additionally, a substantial proportion of data was miss-
ing, with unknown grade (29%) or depth of invasion
(33%). Therefore, a well-controlled study that addresses
all the above-mentioned concerns is required.
The strengths of this study were that it was conducted
at a single tertiary referral institution performing high-
volume robot-assisted surgery for cervical cancer and
that it compared robotic surgery alone with ARH. Add-
itionally, the characteristics of the included patient
population were similar to those of patients included in
the LACC trial. Thus, the concerns raised by the
Fig. 2 Survival analysis. Comparison of progression-free survival (a, b) and overall survival (c, d) in ARH vs. RRH (a, c) and ARH vs. RRH1 vs. RRH2
(b, c). RRH, robotic radical hysterectomy; ARH, abdominal radical hysterectomy
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relatively small number of RRHs in the LACC trial can
be addressed. However, there are several limitations re-
lated to the retrospective design of this study, including
the potential for selection bias, unmeasured con-
founders, and missing data that may have affected data
analysis.
Conclusions
Our study found that institutional experience with ro-
botic surgery, represented by the operation year, is one
of the most significant factors associated with RRH out-
comes for early-stage cervical cancer. We should not
discard all the benefits of robot-assisted laparoscopy by
doing away with the minimally invasive approach for
cervical cancer. Before the well-controlled trial is carried
out, the mode of surgery should be determined accord-
ing to each surgeon’s proficiency. Surgeons are recom-
mended to counsel their patients and decide on the
mode of surgery based on the oncologic outcomes of the
previous institutional patients.
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